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Foreword
A Prescription for Pharmaceutical's
Future: Balancing Industry and Consumer
Concerns in Pharmaceutical Drug
Development
Caroline Bressman*
Prescription drug pricing is an explosive issue for contempo-
rary Americans.' Despite intense calls to action, few changes
have followed. After years of protest, why is there no solution?
Tackling these issues head on, Minnesota Law Review
hosted its annual Symposium-entitled "A Prescription for
Pharmaceutical's Future: Balancing Industry and Consumer
Concerns in Pharmaceutical Drug Development"-on October
27, 2017. Professors, industry insiders, consumer advocates, and
federal regulators gathered to discuss the thorny issues sur-
rounding drug pricing.
Ralph Hall, J.D., professor of practice at the University of
Minnesota Law School, launched the Symposium's discussion by
describing why drug pricing is such a key issue for individuals
and for societal structures. Professor Hall outlined the many ar-
eas of law, market dynamics, and social values that drug pricing
traverses. Moreover, he described how the rise of precision med-
icine profoundly impacts drug pricing. When the cost of develop-
ing drugs increases yet the number of people using such drugs
* Symposium Articles Editor, Minnesota Law Review Volume 102. I am
deeply grateful to Professor Ruth L. Okediji and Professor Ralph Hall for provid-
ing invaluable counsel in curating the Symposium. Special thanks also to the
University of Minnesota Law School for furnishing the resources to make the
Symposium a success. Lastly, I thank Minnesota Law Review's Lead Editors
and Professor Kristin Hickman for constant support throughout the Symposium
development process. Copyright 0 2018 by Caroline Bressman.
1. See Ashley Kirzingerm, Bryan Wu, & Mollyan Brodie, Kaiser Health
Tracking Poll-March 2018: Views on Prescription Drug Pricing and Medicare-
for-all Proposals, KAISER FAMILY FOUND. (Mar. 23, 2018), https://www.kff.org/
health-costs/poll-finding/kaiser-health-tracking-poll-march-2018-prescription
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decreases, then that dynamic raises drug prices. At the same
time, medical professionals would consider that dynamic good
medicine. After considering these diverse implications, Professor
Hall raised the deceptively simple question, "What is a 'fair'
price?"
Next, Michelle M. Mello, Ph.D., J.D., professor of law at
Stanford Law School and professor of health research and policy
at Stanford University School of Medicine, described why, out of
the many problems in health policy, drug pricing is the most dif-
ficult problem to solve. Professor Mello described the various
market, moral, and political factors that render solving the drug
pricing issue uniquely difficult. She characterized the funda-
mental difficulty as American society's uncertainty about the
core tradeoff between affordability and availability of innovative
therapies. She explained why drug pricing has egregious issues
with transparency. She elucidated the many examples of per-
verse incentives that abound the prescription drug market. She
noted that pharmaceutical pricing and development issues lack
an ethical framework, largely due to the cognitive dissonance be-
tween innovation and access. Finally, she argued that the cur-
rent political atmosphere, particularly with its emphasis on
pharmaceutical company scandals, makes cool-headed delibera-
tion about solutions even more challenging.
Joanne Chan, J.D., assistant general counsel for the Phar-
maceutical Research and Manufacturers of American (PhRMA),
then outlined the issue of drug pricing from the perspective of
the pharmaceutical industry. She provided context on the im-
portance of research and development and its resource-inten-
siveness in terms of person-power and financing. Ms. Chan fur-
ther explained that many actors influence how a drug is priced
and that the system includes a framework for negotiating dis-
counts and rebates on top of a foundation of competition in the
supply chain. Lastly, she highlighted the need for a collective so-
lution to rising drug prices that would include the interests of
innovators, supply chain players, and patients.
The Symposium then moved into its first panel discussion,
entitled "Investigating the Pricing Equation: A Law and Eco-
nomics Analysis," moderated by Thomas F. Cotter, M.S., J.D.,
Briggs and Morgan professor of law at the University of Minne-
sota Law School. The panel's first speaker, Arti K. Rai, J.D.,
Elvin R. Latty professor of law at Duke University Law School,
addressed the intersection of biopharmaceutical regulation and
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antitrust. She first contrasted pharmaceutical drugs with biolog-
ics in terms of how competition operates differently and how the
Hatch-Waxman Act differs from the Biologics Price Competition
and Innovation Act of 2010 in terms of patent litigation frame-
works. Professor Rai also argued that this sector-specific regula-
tory regime is not sufficiently attentive to competition and that
the U.S. Supreme Court's decision in FTC v. Actavis, in which
the Court reasoned that reverse payment deals are subject to
significant antitrust scrutiny, was the correct decision. Professor
Rai argued that even though antitrust should not be excluded, it
should also not act as the sole remedy for the lack of competition
that may emerge from regulatory dysfunction. She provided
cases in which she argued that reliance on antitrust is dubious,
such as in the case of product hopping.
The panel's second speaker, Christopher Robertson, Ph.D.,
J.D., professor of law and associate dean for research and inno-
vation at the University of Arizona College of Law, presented
aspects of a forthcoming book project. Professor Robertson's talk
focused on the consumer side of the pharmaceutical drug pricing
equation, and suggested that health insurance can sometimes
compound the challenges around drug affordability. He outlined
a major issue in health policy: if one exposes consumers to
healthcare costs, then access to healthcare is undermined. At the
same time, though, one cannot rule out the problem of moral
hazard waste in health insurance. To examine the issue of health
insurance creating waste while also creating consumer access,
Professor Robertson presented pilot data of a vignette study that
used indemnity insurance as a lodestar for comparison. The pa-
tient, or the homeowner in the indemnity insurance framework,
may decide how to spend insurance checks, while also retaining
access to services.
Next, Rachel Sachs, M.P.H., J.D., associate professor of law
at Washington University School of Law, delivered a discussion
of the relationship between FDA approval and insurance impact,
along with that relationship's impact on drug pricing. Although
many policymakers often do not recognize this relationship, Pro-
fessor Sachs explained that significant overlap of the FDA ap-
proval standard and coverage of drugs by public insurance pro-
grams (such as Medicare) exists. She then queried what might
happen if the FDA approval process and insurance reimburse-
ment was completely delinked and hypothesized that a reduction
in access to drugs would occur. Professor Sachs concluded by de-
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scribing possible options short of full delinkage that could ad-
dress both drug pricing and access issues.
Finally, Stephen Schondelmeyer, Pharm.D., Ph.D., chair of
the Department of Pharmaceutical Care and Health Systems
and director of the PRIME Institute at the University of Minne-
sota, described signals of market failure in the pharmaceutical
market and potential fixes for the future. First, he outlined the
major categories of market failure signals-market structural is-
sues, reverse and perverse incentives, extraordinary prices and
extraordinary price changes, occasional irrational prescribing,
and market inefficiencies-and described these signals as char-
acteristics of the pharmaceutical market. Professor Schon-
delmeyer noted the uniqueness of the pharmaceutical market:
as prices increase, the value of a drug and a consumer's health
state does not necessarily increase in turn. In concluding his
talk, Dr. Schondelmeyer argued that increased transparency of
pricing information, accountability for drug prices charged by
pharmaceutical companies, and targeted rewards for significant
innovations are necessary reforms for the pharmaceutical mar-
ket.
The Symposium's keynote speaker was Dr. Jonathan Jarow,
senior medical advisor to the director of the FDA's Center for
Drug Evaluation and Research. Dr. Jarrow delivered an address
on the FDA's mission and its actions with respect to pharmaceu-
tical drug development. He noted that the Agency's core mission
constitutes a balance between protecting the public and spurring
innovation, and, with respect to drug development, balancing
safety and access in a field with limited resources. Dr. Jarow pro-
vided the opioid epidemic as an example of the FDA applying its
mission to an immensely challenging situation and taking un-
precedented actions to meet its mission. He emphasized that alt-
hough the FDA has not directly regulated drug pricing during
its history, the Agency has recently changed its policy by taking
actions that indirectly affect drug pricing as a means of render-
ing drugs more accessible to the public.
The Symposium's second panel, titled "'Safe and Effective'
or 'Now and Cheap?': Finding the Right Role for the FDA," was
moderated by Professor Ralph Hall. Amy Kapczynski, M.A., J.D.,
professor of law and faculty director of the Global Health Justice
Partnership at Yale Law School, opened the discussion by ana-
lyzing the FDA's mission and recent backlash efforts from
groups that argue that the government should not regulate what
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drugs are available. She provided three examples of these back-
lash efforts: (1) so-called right to try legislation; (2) provisions
from the 21st Century Cures Act; and (3) First Amendment liti-
gation regarding drug marketing. Professor Kapczynski defined
the FDA's mission as both a producer of balanced information
about drugs and a validator of information on drugs, both func-
tions at which the market often fails. She argued that calls to
decrease the FDA's role must be preceded by more consideration
of the reliability of FDA decision making on accelerated time-
lines and with less evidence. She then pointed out that infor-
mation generation and validation could operate in other man-
ners, such as with publicly funded clinical trials and mandates
for data transparency.
Next, Jordan Paradise, J.D., professor of law at Loyola Chi-
cago School of Law, spoke on regulatory silence at the FDA.
First, she described what the FDA is and what its general au-
thority is regarding drugs and biologics regulation. Significantly,
she emphasized that Congress has authorized the FDA to act,
without requiring specific action, on patent law issues. She then
described the complex relationship between the FDA, the Fed-
eral Trade Commission, and the U.S. Patent and Trademark Of-
fice. She provided two examples of the FDA's inaction regarding
patent-related procedural mechanisms within legislation: risk
evaluation and mitigation strategies for drugs and biologics and
the Biologics Price Competition and Innovation Act. Finally, she
described potential costs associated with the Agency's decision
not to act, including litigation costs, delayed market entry, in-
creased drug costs, decreased competition, and adverse patient
outcomes.
W. Nicholson Price II, J.D., Ph.D., assistant professor of law
at University of Michigan Law School, then concluded the panel
by analyzing how the tools of a learning health system could help
with the balancing of gaining access to drugs early with less in-
formation or gaining access later with more information. Profes-
sor Price described how clinical trials are not the best method of
learning a drug's efficacy and safety. Instead, a learning health
system model would provide opportunities for a cycle of constant
information collection and improvement of pharmaceutical
drugs. Professor Price outlined two examples-observational
studies and interventional studies with electronic health record
systems-that could be incorporated in the drug approval re-
gime. Despite these possibilities, however, Professor Price also
explained how the legal frameworks of research and clinical
2018] 2269
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care, specifically with each framework's rules on privacy and in-
formed consent, would hamper a learning health system model.
The third and final panel, titled "Pharmaceuticals Around
the Globe: Access and Delivery Issues for Consumers," was mod-
erated by Fred L. Morrison, Ph.D., J.D., Popham, Haik, Schno-
brichlLindquist & Vennum professor of law at the University of
Minnesota Law School. James Love, director of Knowledge Ecol-
ogy International, delivered a talk on the balance of innovation
and affordability tradeoffs and the "delinkage" of a pharmaceu-
tical market that does not rely on high prices. He described how
current calls for delinkage emphasize competition, such as by
creating a prize fund with a mechanism to compete for shares of
this fund, based on evidence of efficacy relative to competing
drugs. Mr. Love also argued that inquiries on drug prices should
not be based solely on value, but should focus on how much
money a company needs to do what consumers want it to do. Fi-
nally, Mr. Love provided an example of how a remuneration and
innovation fund could apply to CAR T-cell therapy in the treat-
ment of some kinds of cancer.
Next, Jerome J. Reichman, J.D., Bunyan S. Womble profes-
sor of law at Duke University Law School, presented on compul-
sory licensing of pharmaceutical drugs under the Agreements on
Trade Related Aspects of Intellectual Property Rights (TRIPS)
of 1994. Professor Reichman described how prices for patented
medicines remain high in most developing countries because of
TRIPS and how he has previously argued that developing coun-
tries should consider pooled procurement strategies to gain ac-
cess to essential medicines. Professor Reichman then described
how the recent Marrakesh Treaty provides a framework for
cross-border action that suspends the ordinary rules of territo-
rial intellectual property laws in the service of human rights.
The Marrakesh Treaty may serve as an analogy to pharmaceu-
tical access, in which governments in pharmaceutical producer
countries would issue compulsory licenses solely for the export
of such pharmaceuticals to requesting countries under Article
31bis of TRIPS.
Finally, Margo A. Bagley, J.D., Asa Griggs Candler profes-
sor of law at Emory University School of Law, described the in-
creasing interest in several countries for legitimizing traditional
medical systems in healthcare. She explained the differences be-
tween traditional medicines and scientific medicines and that
the former remains the primary source for healthcare for many
people, particularly in developing countries. Although the two
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systems have similarities, Professor Bagley explained that coun-
tries should not push traditional medicines as a substitute for
scientific medicine when the efficacy of traditional medicine has
not been proven, particularly since information gathering and
validation of traditional medicines proves burdensome. How-
ever, if traditional medicines are as efficacious as scientific med-
icines, then the former's integration into a healthcare system
could lower the overall pharmaceutical cost burden. Finally, Pro-
fessor Bagley described the importance of reconceptualizing a
broader concept of access to medicines, which would include is-
sues such as lifestyle changes regarding diet and exercise as ac-
cess to medicines issues.
Minnesota Law Review's 2017 Symposium discussions illus-
trated why pharmaceutical drug pricing is one of the most com-
plex legal and policy issues today. Common themes resonated
among many of the speaker's talks, such as the uniqueness of
the pharmaceutical market and its constant battle between ac-
cess and innovation, yet each speaker focused on a discrete as-
pect of the market and its regulation in offering novel solutions
to today's astronomical drug pricing issues. The following pieces
provide a deeper look into the Symposium's discussions. No sin-
gle prescription exists as a panacea to drug pricing issues today,
but sustained conversation of ideas raised at this Symposium
provides a foundation for pharmaceutical's future.
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